Document Detail


A cost density analysis of benign prostatic hyperplasia.
MedLine Citation:
PMID:  8930437     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We assessed the frequency and cost of care for benign prostatic hyperplasia (BPH) among approximately 165,000 subscribers to Fallon Community Health Plan (FCHP), a group model health maintenance organization located in central Massachusetts. We computed rates of episodes of medical services for BPH using automated utilization files, and we estimated costs using Medicare reimbursement schedules and medication average wholesale prices. We identified 3919 men who visited a physician for BPH from January 1, 1991, until December 31, 1994, during which time they contributed 8336 person-years to the analysis. This population comprises approximately 12% of men at least 40 years old at FCHP. From 1991 to 1994, 696 (18%) men received terazosin, 219 (6%) men underwent a prostatectomy, and 41 (1%) men received finasteride. Men averaged 1.66 office visits per year to a physician for BPH. Most office visits (61%) were to a primary care physician, with 39% of the visits to a urologist. Among patients who received terazosin, the frequency of office visits increased slightly after receiving terazosin, from 2.14 to 2.62 visits per year. Among surgery patients, the frequency of visits declined after prostatectomy, from 6.31 visits per year to 1.67 visits. The individual annual cost rate for BPH care ranged from $25.00 to $25,352.00, with an average of $364.00 per person and a median cost of $126.00. The major components of the overall costs were hospital admissions (35%), terazosin dispensings (29%), and physician office visits (19%), with outpatient hospital care and ambulatory procedures accounting for the remaining 17%. Among men receiving terazosin, the average cost was $1190.00 per person-year, and among patients undergoing prostatectomy, the cost was $2630.00 per person-year. The prostatectomy rate declined by nearly 80% during the study period, while the dispensing rate for terazosin doubled, resulting in an overall decline in the total cost of care for BPH from 1991 to 1994.
Authors:
S F Lanes; S Sulsky; A M Walker; J Isen; C E Grier; B E Lewis; N A Dreyer
Related Documents :
7582337 - Leg ulcer treatment in hospital and primary care in sweden: cost-effective care and qua...
18842157 - Costs and quality of life for prehabilitation and early rehabilitation after surgery of...
8644957 - Cost-effectiveness analysis of potential improvements to emergency medical services for...
15182757 - Workers' compensation costs: still a challenge.
24261337 - Developing a toolkit for panel management: improving hypertension and smoking cessation...
16171447 - Treatment of gingival fibromatosis associated with zimmermann-laband syndrome.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical therapeutics     Volume:  18     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:    1996 Sep-Oct
Date Detail:
Created Date:  1997-02-12     Completed Date:  1997-02-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  993-1004     Citation Subset:  IM    
Affiliation:
Epidemiology Resources Inc., Newton Lower Falls, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Drug Costs
Health Care Costs
Hospital Costs
Humans
Incidence
Male
Massachusetts
Middle Aged
Prostatic Hyperplasia / economics*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluating quality-of-life and health status instruments: development of scientific review criteria.
Next Document:  Gammagard and reported hepatitis C virus episodes.